Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in Lund – page 14

327 clinical trials in Lund, Sweden across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Lund at a glance
327
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

327 trials in Lund

Open in trial search

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Non-small cell lung cancer

Not yet recruiting

Phase II Randomized Trial of Adjuvant Durvalumab Immunotherapy After Neoadjuvant Chemoimmunotherapy in Patients With Resectable Non‑Small Cell Lung Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Oslo University Hospital HF

Parkinson's disease

Not yet recruiting

A Randomized Trial of lu af28996 dh1 to Reduce Motor Fluctuations in Adults with Parkinson’s Disease

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Sponsor:H. Lundbeck A/S

Pulmonary embolism

Not yet recruiting

Reduced-dose versus full-dose alteplase for high-risk acute pulmonary embolism patients: a randomized multicenter trial

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:University Of Gothenburg

A Phase III study of AZD0120 with drug combination versus standard therapy in adults with newly diagnosed multiple myeloma not eligible for stem cell transplant

Not yet recruiting
Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Small cell lung cancer limited stage

Not yet recruiting

Durvalumab after chemoradiation for patients with limited‑stage small cell lung cancer: a randomized trial of high‑dose versus standard thoracic radiation

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Norwegian University Of Science And Technolology

Malignant melanoma stage IV+1

Not yet recruiting

Phase Ib/II study of momelotinib with nivolumab or pembrolizumab in unresectable stage III/IV cutaneous melanoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Karolinska University Hospital

Palliative care

Not yet recruiting

Morphine Hydrochloride for Resting Breathlessness in Adults with Serious Chronic Life‑Limiting Disease Receiving Palliative Care

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Region Skane

Metachromatic leukodystrophy

Not yet recruiting

Long‑Term Monitoring of Malignancy Risk in Early‑Onset Metachromatic Leukodystrophy Patients Treated with atidarsagene autotemcel

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Atidarsagene Autotemcel
  • Sponsor:Orchard Therapeutics (Europe) Limited

Parkinson's disease

Not yet recruiting

Montelukast Sodium for disease-modifying treatment in patients with mild‑moderate Parkinson’s disease: open‑label phase II extension study

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Montelukast Sodium
  • Sponsor:Karolinska University Hospital

Dermatitis atopic

Not yet recruiting

A Study of Lebrikizumab for Adults and Adolescents with Moderate to Severe Atopic Dermatitis to Evaluate Effects on Eczema and Skin Barrier Function

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Lebrikizumab
  • Sponsor:Region Oestergoetland

COVID-19

Not yet recruiting

Study of Intravenous Immunoglobulin Added to Standard Treatment for COVID-19 in Patients with Severely Weakened Immune System Due to B-cell Problems

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Nirmatrelvir
  • Sponsor:Region Vaesterbotten

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Lund

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on chronic coronary syndrome and heart failure prevention, including investigations of hyperemic responses and new combination therapies.

  • Adenosine response studies
  • Heart failure prevention trials
  • Lipoprotein management

Advanced cardiovascular research exploring novel treatment approaches for various cardiac conditions.

02 Oncology Studies

Comprehensive research in multiple cancer types, including melanoma, leukemia, and colorectal cancer, testing innovative therapeutic approaches.

  • Immunotherapy trials
  • Blood cancer treatments
  • Targeted therapy studies

Focus on developing more effective and personalized cancer treatments.

03 Mental Health & Neurology

Groundbreaking research in mental health conditions, including studies of anorexia nervosa and major depressive disorder.

  • Psychedelic therapy research
  • Depression treatment studies
  • Innovative therapeutic approaches

Exploring novel treatment modalities for complex psychiatric conditions.

Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.